$ELOX
Eloxx Pharmaceuticals, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023062940 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.387M
YoY Change 5.53%
% of Gross Profit
Research & Development $1.250M
YoY Change -74.39%
% of Gross Profit
Depreciation & Amortization $13.00K
YoY Change -43.48%
% of Gross Profit
Operating Expenses $3.637M
YoY Change -49.08%
Operating Profit -$3.637M
YoY Change -49.08%
Interest Expense -$238.0K
YoY Change -34.97%
% of Operating Profit
Other Income/Expense, Net $45.00K
YoY Change -112.3%
Pretax Income -$3.592M
YoY Change -52.16%
Income Tax
% Of Pretax Income
Net Earnings -$3.592M
YoY Change -52.16%
Net Earnings / Revenue
Basic Earnings Per Share -$1.31
Diluted Earnings Per Share -$1.31
COMMON SHARES
Basic Shares Outstanding 3.143M 2.753M
Diluted Shares Outstanding 2.748M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.775M
YoY Change -80.55%
Cash & Equivalents $4.775M
Short-Term Investments
Other Short-Term Assets $854.0K
YoY Change -23.55%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.629M
YoY Change -78.07%
LONG-TERM ASSETS
Property, Plant & Equipment $107.0K
YoY Change -50.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $413.0K
YoY Change -65.81%
TOTAL ASSETS
Total Short-Term Assets $5.629M
Total Long-Term Assets $413.0K
Total Assets $6.042M
YoY Change -77.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.134M
YoY Change 96.49%
Accrued Expenses $2.442M
YoY Change -45.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $2.819M
YoY Change 11.42%
Total Short-Term Liabilities $23.47M
YoY Change 8.24%
LONG-TERM LIABILITIES
Long-Term Debt $2.621M
YoY Change -73.43%
Other Long-Term Liabilities $3.000K
YoY Change -99.06%
Total Long-Term Liabilities $2.621M
YoY Change -73.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.47M
Total Long-Term Liabilities $2.621M
Total Liabilities $26.09M
YoY Change -18.11%
SHAREHOLDERS EQUITY
Retained Earnings -$288.6M
YoY Change 7.65%
Common Stock $268.5M
YoY Change 1.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$20.05M
YoY Change
Total Liabilities & Shareholders Equity $6.042M
YoY Change -77.52%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$3.592M
YoY Change -52.16%
Depreciation, Depletion And Amortization $13.00K
YoY Change -43.48%
Cash From Operating Activities -$3.450M
YoY Change -50.33%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $233.0K
YoY Change
Cash From Investing Activities $233.0K
YoY Change -585.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.670M
YoY Change 144.67%
NET CHANGE
Cash From Operating Activities -3.450M
Cash From Investing Activities 233.0K
Cash From Financing Activities 3.670M
Net Change In Cash 453.0K
YoY Change -108.25%
FREE CASH FLOW
Cash From Operating Activities -$3.450M
Capital Expenditures $0.00
Free Cash Flow -$3.450M
YoY Change -49.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001035354
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31326
dei Entity Registrant Name
EntityRegistrantName
ELOXX PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1368850
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1368850
dei Entity Address Address Line1
EntityAddressAddressLine1
480 Arsenal Way
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
577-5300
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
ELOX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3143390
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4775000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19207000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
219000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
261000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
635000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
661000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
5629000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
20129000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
107000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
169000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
306000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
825000
CY2023Q3 us-gaap Assets
Assets
6042000
CY2022Q4 us-gaap Assets
Assets
21123000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3134000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3020000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2442000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2799000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2819000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3980000
CY2023Q3 elox Advances From Collaboration Partners Current
AdvancesFromCollaborationPartnersCurrent
12966000
CY2022Q4 elox Advances From Collaboration Partners Current
AdvancesFromCollaborationPartnersCurrent
12535000
CY2023Q3 elox Warrant Liabilities Current
WarrantLiabilitiesCurrent
1695000
CY2022Q4 elox Warrant Liabilities Current
WarrantLiabilitiesCurrent
0
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
315000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
712000
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
95000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
45000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
23466000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23091000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2621000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8557000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
135000
CY2023Q3 us-gaap Liabilities
Liabilities
26090000
CY2022Q4 us-gaap Liabilities
Liabilities
31783000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3068390
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3068390
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2166356
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2166356
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
31000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
268472000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
263706000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-288551000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-274388000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-20048000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10660000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6042000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21123000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1250000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4880000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7076000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20430000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2387000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2262000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6184000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7961000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3637000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7142000
us-gaap Operating Expenses
OperatingExpenses
13260000
us-gaap Operating Expenses
OperatingExpenses
28391000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3637000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7142000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13260000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28391000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-366000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-903000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1355000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3592000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7508000
us-gaap Net Income Loss
NetIncomeLoss
-14163000
us-gaap Net Income Loss
NetIncomeLoss
-29746000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.47
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.73
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2747687
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2747687
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166404
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166404
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2377599
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2377599
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166344
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166344
us-gaap Profit Loss
ProfitLoss
-14163000
us-gaap Profit Loss
ProfitLoss
-29746000
us-gaap Share Based Compensation
ShareBasedCompensation
1625000
us-gaap Share Based Compensation
ShareBasedCompensation
2380000
us-gaap Depreciation
Depreciation
40000
us-gaap Depreciation
Depreciation
67000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
519000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
450000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
217000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
397000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
50000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
116000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-273000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
elox Loss On Extinguishment Of Term Debt
LossOnExtinguishmentOfTermDebt
406000
elox Loss On Extinguishment Of Term Debt
LossOnExtinguishmentOfTermDebt
0
elox Loss On Issuance Of Common Stock
LossOnIssuanceOfCommonStock
231000
elox Loss On Issuance Of Common Stock
LossOnIssuanceOfCommonStock
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
255000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-26000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-59000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
133000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
216000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-357000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
322000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-529000
elox Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-445000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12330000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26184000
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
258000
us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
258000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66000
elox Proceeds From The Issuance Of Common Stock Pre Funded Warrants And Common Stock Warrants
ProceedsFromTheIssuanceOfCommonStockPreFundedWarrantsAndCommonStockWarrants
1737000
elox Proceeds From The Issuance Of Common Stock Pre Funded Warrants And Common Stock Warrants
ProceedsFromTheIssuanceOfCommonStockPreFundedWarrantsAndCommonStockWarrants
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3150000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7720000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
431000
elox Proceeds From Advances From Collaboration Partners
ProceedsFromAdvancesFromCollaborationPartners
8500000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2402000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8500000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14474000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17750000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19468000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42567000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4994000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24817000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4775000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24554000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
219000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
263000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4994000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24817000
us-gaap Interest Paid Net
InterestPaidNet
819000
us-gaap Interest Paid Net
InterestPaidNet
968000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10660000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
597000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6230000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
16293000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
228000
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1428000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
610000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4341000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-18596000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
263000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
124000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
124000
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1722000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
418000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3592000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-20048000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22384000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
922000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11620000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11686000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
744000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10618000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1812000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
714000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7508000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4982000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-288600000
CY2023Q3 elox Cash And Cash Equivalent And Available For Sale Debt Securities
CashAndCashEquivalentAndAvailableForSaleDebtSecurities
4800000
CY2023Q3 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
249000
CY2022Q4 elox Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
366000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
249000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
93000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
137000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
202000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
635000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
661000
CY2023Q3 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1873000
CY2022Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1544000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
122000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
750000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
278000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
225000
CY2023Q3 elox Accrued Interest On Debt
AccruedInterestOnDebt
62000
CY2022Q4 elox Accrued Interest On Debt
AccruedInterestOnDebt
146000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
107000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
134000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2442000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2799000
CY2022Q4 us-gaap Long Term Debt Percentage Bearing Variable Interest Rate
LongTermDebtPercentageBearingVariableInterestRate
0.1375
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
681000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2987000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1112000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
4780000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
159000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
4621000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2819000
CY2023Q3 elox Long Term Debt Maturities Final Fee Due
LongTermDebtMaturitiesFinalFeeDue
-819000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2621000
elox Royalties Percentage Of Net Sales Based On Actual Amount Of Funding
RoyaltiesPercentageOfNetSalesBasedOnActualAmountOfFunding
0.06
elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P5Y6M
CY2023Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
elox Net Cash Proceeds
NetCashProceeds
1700000
elox Loss On Issuance Of Common Stock
LossOnIssuanceOfCommonStock
200000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1021
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
479446
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
249403
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
105.87
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M13D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
221395
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
59413
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
17.06
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
411385
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
64.02
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y5M23D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
132907
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
152.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M17D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
75000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.29
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
75000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.29
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
418000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
714000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1625000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2380000
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
235000
CY2022Q3 us-gaap Interest Expense Other
InterestExpenseOther
489000
us-gaap Interest Expense Other
InterestExpenseOther
950000
us-gaap Interest Expense Other
InterestExpenseOther
1368000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
20000
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
108000
us-gaap Interest And Other Income
InterestAndOtherIncome
245000
us-gaap Interest And Other Income
InterestAndOtherIncome
133000
CY2023Q3 elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
0
CY2022Q3 elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
0
elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
406000
elox Loss On Extinguishment Of Debt
LossOnExtinguishmentOfDebt
0
CY2023Q3 elox Loss On Issuance Of Common Stock
LossOnIssuanceOfCommonStock
231000
CY2022Q3 elox Loss On Issuance Of Common Stock
LossOnIssuanceOfCommonStock
0
elox Loss On Issuance Of Common Stock
LossOnIssuanceOfCommonStock
231000
elox Loss On Issuance Of Common Stock
LossOnIssuanceOfCommonStock
0
CY2023Q3 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-255000
CY2022Q3 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-255000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-35000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-33000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4000
CY2023Q3 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
20000
CY2022Q3 elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-50000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
50000
elox Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
116000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-273000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-273000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
14000
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
6000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
0
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-366000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-903000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1355000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3592000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7508000
us-gaap Net Income Loss
NetIncomeLoss
-14163000
us-gaap Net Income Loss
NetIncomeLoss
-29746000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2747687
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2747687
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166404
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166404
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2377599
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2377599
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2166344
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2166344
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.31
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.31
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.47
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.73
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
890831
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
264232
CY2023Q3 elox Pre Funded Common Warrants
PreFundedCommonWarrants
75000

Files In Submission

Name View Source Status
elox-20230930_lab.xml Edgar Link unprocessable
elox-20230930_def.xml Edgar Link unprocessable
0000950170-23-062940-index-headers.html Edgar Link pending
0000950170-23-062940-index.html Edgar Link pending
0000950170-23-062940.txt Edgar Link pending
0000950170-23-062940-xbrl.zip Edgar Link pending
elox-20230930.htm Edgar Link pending
elox-20230930.xsd Edgar Link pending
elox-ex10_1.htm Edgar Link pending
elox-ex10_2.htm Edgar Link pending
elox-ex10_3.htm Edgar Link pending
elox-ex10_4.htm Edgar Link pending
elox-ex10_5.htm Edgar Link pending
elox-ex31_1.htm Edgar Link pending
elox-ex31_2.htm Edgar Link pending
elox-ex32_1.htm Edgar Link pending
elox-ex32_2.htm Edgar Link pending
elox-ex4_1.htm Edgar Link pending
elox-ex4_2.htm Edgar Link pending
elox-ex4_3.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
elox-20230930_cal.xml Edgar Link unprocessable
elox-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
elox-20230930_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending